308 related articles for article (PubMed ID: 26681546)
1. Can galectin-3 be a useful marker for conventional papillary thyroid microcarcinoma?
Gweon HM; Kim JA; Youk JH; Hong SW; Lim BJ; Yoon SO; Park YM; Son EJ
Diagn Cytopathol; 2016 Feb; 44(2):103-7. PubMed ID: 26681546
[TBL] [Abstract][Full Text] [Related]
2. Deciphering novel biomarkers of lymph node metastasis of thyroid papillary microcarcinoma using proteomic analysis of ultrasound-guided fine-needle aspiration biopsy samples.
Lin P; Yao Z; Sun Y; Li W; Liu Y; Liang K; Liu Y; Qin J; Hou X; Chen L
J Proteomics; 2019 Jul; 204():103414. PubMed ID: 31195151
[TBL] [Abstract][Full Text] [Related]
3. Absence of galectin-3 immunostaining in fine-needle aspiration cytology specimens from papillary thyroid carcinoma is associated with favorable pathological indices.
Kim ES; Lim DJ; Lee K; Jung CK; Bae JS; Jung SL; Baek KH; Lee JM; Moon SD; Kang MI; Cha BY; Lee KW; Son HY
Thyroid; 2012 Dec; 22(12):1244-50. PubMed ID: 22892040
[TBL] [Abstract][Full Text] [Related]
4. Contribution of immunocytochemical stainings for galectin-3, CD44, and HBME1 to fine-needle aspiration cytology diagnosis of papillary thyroid carcinoma.
Das DK; Al-Waheeb SK; George SS; Haji BI; Mallik MK
Diagn Cytopathol; 2014 Jun; 42(6):498-505. PubMed ID: 24273003
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 is not useful in thyroid FNA.
Mills LJ; Poller DN; Yiangou C
Cytopathology; 2005 Jun; 16(3):132-8. PubMed ID: 15924608
[TBL] [Abstract][Full Text] [Related]
6. Preoperative ultrasonography and serum thyroid-stimulating hormone on predicting central lymph node metastasis in thyroid nodules as or suspicious for papillary thyroid microcarcinoma.
Gao Y; Qu N; Zhang L; Chen JY; Ji QH
Tumour Biol; 2016 Jun; 37(6):7453-9. PubMed ID: 26678888
[TBL] [Abstract][Full Text] [Related]
7. Extrathyroid extension of well-differentiated papillary thyroid microcarcinoma on US.
Kwak JY; Kim EK; Youk JH; Kim MJ; Son EJ; Choi SH; Oh KK
Thyroid; 2008 Jun; 18(6):609-14. PubMed ID: 18578609
[TBL] [Abstract][Full Text] [Related]
8. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma.
Lin KL; Wang OC; Zhang XH; Dai XX; Hu XQ; Qu JM
Ann Surg Oncol; 2010 Dec; 17(12):3294-300. PubMed ID: 20953721
[TBL] [Abstract][Full Text] [Related]
9. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions].
Tong J; Wang Y; Da JP
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220
[TBL] [Abstract][Full Text] [Related]
10. Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two?
Arora N; Turbendian HK; Kato MA; Moo TA; Zarnegar R; Fahey TJ
Thyroid; 2009 May; 19(5):473-7. PubMed ID: 19348582
[TBL] [Abstract][Full Text] [Related]
11. Real-Time PCR Cycle Threshold Values for the BRAFV600E Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis: A Retrospective Study.
Park VY; Kim EK; Lee HS; Moon HJ; Yoon JH; Kwak JY
Medicine (Baltimore); 2015 Jul; 94(28):e1149. PubMed ID: 26181555
[TBL] [Abstract][Full Text] [Related]
12. Galectin-1 is a diagnostic marker involved in thyroid cancer progression.
Arcolia V; Journe F; Wattier A; Leteurtre E; Renaud F; Gabius HJ; Remmelink M; Decaestecker C; Rodriguez A; Boutry S; Laurent S; Saussez S
Int J Oncol; 2017 Sep; 51(3):760-770. PubMed ID: 28677745
[TBL] [Abstract][Full Text] [Related]
13. Split sample comparison of a liquid-based method and conventional smears in thyroid fine needle aspiration.
Jung CK; Lee A; Jung ES; Choi YJ; Jung SL; Lee KY
Acta Cytol; 2008; 52(3):313-9. PubMed ID: 18540296
[TBL] [Abstract][Full Text] [Related]
14. [Papillary thyroid microcarcinoma].
Xie P; Deng H; Tan T
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Oct; 26(5):1167-70. PubMed ID: 19947513
[TBL] [Abstract][Full Text] [Related]
15. Gray-scale ultrasonography combined with elastography imaging for the evaluation of papillary thyroid microcarcinoma: as a prognostic clinicopathology factor.
Jin ZQ; Lin MY; Hu WH; Li WY; Bai SJ
Ultrasound Med Biol; 2014 Aug; 40(8):1769-77. PubMed ID: 24768485
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of epidermal growth factor receptor, p53 and galectin-3 expression in papillary thyroid carcinoma.
Lee YM; Lee JB
J Int Med Res; 2013 Jun; 41(3):825-34. PubMed ID: 23569038
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological, immunohistochemical factors and recurrence associated with extrathyroidal extension in papillary thyroid microcarcinoma.
Kim WY; Kim HY; Son GS; Bae JW; Lee JB
J Cancer Res Ther; 2014; 10(1):50-5. PubMed ID: 24762486
[TBL] [Abstract][Full Text] [Related]
18. Galectin-3 immunodetection may improve cytological diagnosis of occult papillary thyroid carcinoma.
Pisani T; Vecchione A; Giovagnolii MR
Anticancer Res; 2004; 24(2C):1111-2. PubMed ID: 15154632
[TBL] [Abstract][Full Text] [Related]
19. Papillary thyroid microcarcinoma presenting as lymph node metastasis--a diagnostic challenge: case report and systematic review of literature.
Anastasilakis AD; Polyzos SA; Makras P; Kampas L; Valeri RM; Kyriakoulis D; Zarampoukas T; Alevizaki M
Hormones (Athens); 2012; 11(4):419-27. PubMed ID: 23422764
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of whole-exome sequencing in fine-needle aspiration specimens of papillary thyroid microcarcinoma for the identification of novel gene mutations.
Ma L; Gao L; Hu Y; Li X; Liu C; Ji J; Shi X; Pan A; An Y; Luo N; Xia Y; Jiang Y
Clin Genet; 2024 May; 105(5):567-572. PubMed ID: 38326996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
